We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
Background : A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations in exon 19 or 21 . Methods : Eligible patients were r and omised to receive erlotinib ( 150 mg per day ) or gefitinib ( 250 mg per day ) orally until disease progression or unacceptable toxicity . We aim ed to determine whether erlotinib is superior to gefitinib in efficacy . The primary end point was progression-free survival . Results : A total of 256 patients were r and omised to receive erlotinib ( N=128 ) or gefitinib ( N=128 ) . Median progression-free survival was not better with erlotinib than with gefitinib ( 13.0 vs 10.4 months , 95 % confidence interval ( CI ) 0.62–1.05 , P=0.108 ) . The corresponding response rates and median overall survival were 56.3 % vs 52.3 % ( P=0.530 ) and 22.9 vs 20.1 months ( 95 % CI 0.63–1.13 , P=0.250 ) , respectively . There were no significant differences in grade 3/4 toxicities between the two arms ( P=0.172 ) . Conclusions : The primary end point was not met . Erlotinib was not significantly superior to gefitinib in terms of efficacy in advanced non-small cell lung cancer with epidermal growth factor receptor mutations in exon 19 or 21 , and the two treatments had similar toxicities
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV